Generative quantum AI: Engineering the next generation of precision medicine and genomics

Quantum AI’s Transformative Power: Revolutionizing Precision Medicine and Drug Discovery

Ms. Elvira Shishenina, Senior Director of Strategic Initiatives at Quantinuum, a global quantum computing leader, discussed advancements in targeted drug delivery and precision medicine. Quantinuum, with operations in the US, UK, and a new Doha joint venture, has made significant progress in quantum hardware and software, focusing on real-world healthcare applications.

Drug discovery is complex, demanding high accuracy and speed. Classical computational methods often fail to simulate atomistic-level processes, leading to lost drug leads and prolonged development cycles. This inefficiency, exacerbated by extensive clinical trials for data, makes the current process unsustainable for new drug development.

Quantinuum explores Metal Organic Frameworks (MOFs) for precision medicine. These modular particles, with pores, organic linkers, and metallic nodes, earned a Nobel Prize in Chemistry. MOFs show immense promise as drug delivery agents, photodynamic therapy components for cancer, and contrast agents in medical imaging due to their versatility.

However, MOFs’ intricate modularity and quantum interactions pose significant computational hurdles. Classical methods cannot handle their combinatorial complexity or accurately model critical quantum phenomena like photochemistry and excited states. Scaling these simulations for entire surfaces further exposes traditional computing’s limitations.

Recognizing classical AI’s reliance on vast, high-quality data from time-consuming clinical trials, the scientific community is shifting towards quantum computing. This transformative solution enables “atoms to compute with atoms,” aiming for extreme precision at exponentially reduced computational expense, providing superior accuracy over approximate classical methods.

By integrating quantum modeling into drug discovery’s simulation and verification stages, and feeding this precise quantum data back into classical generative AI, the entire process can be dramatically optimized. This hybrid workflow is expected to significantly boost performance, shorten drug development timelines, and improve new therapy success rates.

Quantinuum’s strategy involves three pillars: leveraging extensive MOF research, developing a robust generative AI quantum workflow integrated with HPC data centers, and deploying advanced quantum computers. Their full-stack approach, from hardware to software, ensures seamless operation, exemplified by the recent launch of their powerful Helios machine.

The Rimo MOF, in Stage 2 clinical trials for targeted cancer drug delivery, is a key use case. Understanding its behavior is crucial for optimizing photodynamic therapies. Light excites the MOF, leading to energy transitions that generate singlet oxygens, effectively destroying tumor cells. Precise modeling of this pathway enhances treatment efficiency.

Quantinuum announced a groundbreaking achievement: the world’s largest direct energy correlation evaluation on a quantum computer. This delivered chemical-level accuracies in simulating excited states on a real-life model. This direct quantum computation of quantum phenomena represents the most precise excited state computations ever on quantum machines. Quantinuum aims for practical quantum advantages within this decade through global collaborations.